OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

HTML

Year: 2010
Type: article
Study design: Clinical Trial
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2009.25.4847
Authors: Jean-Charles Soria, Egbert Smit, David Khayat, Benjamin Besse, Xinqun Yang, Cheng-Pang Hsu, David Reese, Jeffrey Wiezorek, Fiona Blackhall
Institutions: Institut Gustave Roussy, Pitié-Salpêtrière Hospital, The Christie NHS Foundation Trust, Amsterdam UMC Location Vrije Universiteit Amsterdam
Language: English

Topic: Lung Cancer Treatments and Mutations
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: TRAIL, Apo2L, non-small cell lung cancer, non-squamous non-small cell lung cancer, paclitaxel, carboplatin, bevacizumab, combination chemotherapy, maximum tolerated dose, pharmacokinetics, dose-limiting toxicity, anticancer activity, recurrent NSCLC, pleural effusion
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2156330379
FWCI: 23.6
Cites: 28
Cited by: 242
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms